KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Aurinia Pharmaceuticals (AUPH) EBT Margin (2019 - 2025)

Aurinia Pharmaceuticals (AUPH) has disclosed EBT Margin for 7 consecutive years, with 3408.79% as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, EBT Margin fell 341075.0% year-over-year to 3408.79%, compared with a TTM value of 55.72% through Dec 2025, up 5255.0%, and an annual FY2025 reading of 2636.42%, down 263959.0% over the prior year.
  • EBT Margin was 3408.79% for Q4 2025 at Aurinia Pharmaceuticals, down from 43.5% in the prior quarter.
  • Across five years, EBT Margin topped out at 43.5% in Q3 2025 and bottomed at 5511.05% in Q1 2021.
  • Average EBT Margin over 5 years is 529.03%, with a median of 43.91% recorded in 2023.
  • The sharpest move saw EBT Margin skyrocketed 14498500bps in 2021, then tumbled -341075bps in 2025.
  • Year by year, EBT Margin stood at 139.28% in 2021, then soared by 36bps to 88.59% in 2022, then surged by 34bps to 58.58% in 2023, then skyrocketed by 103bps to 1.96% in 2024, then tumbled by -174076bps to 3408.79% in 2025.
  • Business Quant data shows EBT Margin for AUPH at 3408.79% in Q4 2025, 43.5% in Q3 2025, and 31.65% in Q2 2025.